02 May 2003
5-Aminoisoquinolin-1-one and other water-soluble PARP inhibitors
M. Threadgill, J. Berry, S. Ferrer, I. Parveen, A. Shinkwin, E. WoonMed Sci Monit 2003; 9(1): 71-0 :: ID: 15214
Abstract
Inhibitors of the activity of PARP have applications in the treatment of many disease states. Most of the known inhibitors of PARP mimic the nicotinamide of the substrate NAD+. The consensus pharmacophore for PARP inhibitors is a primary or secondary benzamide with N–H conformationally constrained anti to the carbonyl-arene bond. However, this can also be considered as a ‘pharmacophore’ for insolubility in water. In this presentation, the results of our work on extending this pharmacophore into heterocyclyl carboxamides, into more water-soluble inhibitors and into potential prodrugs will be outlined. For example, 5-substituted isoquinolin-1-ones and 2, 8-substituted quinazolin-4-ones are known [1,2] to be potent inhibitors of PARP; we have shown [3] that the analogous thieno [3,4-c]pyridin-4(5H)-ones and thieno [3,4-d]pyrimidin-4(3H)-ones are also strongly active. New synthetic routes to 5-aminoisoquinolin-1-one (5-AIQ) have been developed [4], making this inhibitor more readily available. 5-AIQ shows IC50 = 250 nM against PARP activity in a broken nuclear preparation; its corresponding IC50 against a mono-ADP-ribosyl transferase (diphtheria toxin) is 80 KM, making 5-AIQ highly selective for PARP. This compound is highly water-soluble as its hydrochloride, making it suitable for rapid i.v. administration. 5-AIQ protects against organ damage in a rat model of haemorrhagic shock at the remarkably low dose of 30 KgŠKg–1. It is similarly active in vivo in models of myocardial infarction and acute lung inflammation. Potential bioreductively activated prodrugs of this and other isoquinolin-1-ones have been synthesised [5,6] and are shown to release drug rapidly in experimental systems; these include 2-(2-nitroimidazol-5-ylmethyl)isoquinolin-1-ones and 1, 2-dimethyl-3-(isoquinolin-1-yloxymethyl)-5-methoxyindole-4, 7-diones. Further developments from these leads are under active research. References: 1.Suto MJ, Turner WR et al: Anti-Cancer Drug Design, 1991; 7: 107 2.Griffin RJ, Pemberton LC et al: Anti-Cancer Drug Design, 1995; 10: 507 3.Shinkwin AE, Whish WJD, Threadgill MD: Bioorg Med Chem, 1999; 7: 297 4.McDonald MC, Mota-Filipe H, Wright JA et al: Br J Pharmacol, 2000; 130: 843 5.Parveen I, Naughton DP et al: Bioorg Med Chem Lett, 1999; 9: 2031 6.Ferrer S, Naughton DP, Parveen I et al: J Chem Soc Perkin Trans, 2002; 1: 335
Keywords: 5-Aminoisoquinolin-1-one, thieno [3,4-c]pyridin-4(5H)-one, prodrug, Solubility, Reperfusion
Editorial
01 May 2024 : Editorial
Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)DOI: 10.12659/MSM.944927
Med Sci Monit 2024; 30:e944927
In Press
12 Mar 2024 : Clinical Research
Tissue Inhibitors of Metalloproteinase 1 (TIMP-1) and 3 (TIMP-3) as New Markers of Acute Kidney Injury Afte...Med Sci Monit In Press; DOI: 10.12659/MSM.943500
12 Mar 2024 : Review article
Optimizing Behçet Uveitis Management: A Review of Personalized Immunosuppressive StrategiesMed Sci Monit In Press; DOI: 10.12659/MSM.943240
12 Mar 2024 : Clinical Research
Metabolomic Alterations in Methotrexate Treatment of Moderate-to-Severe PsoriasisMed Sci Monit In Press; DOI: 10.12659/MSM.943360
14 Mar 2024 : Clinical Research
Renal Dysfunction Increases Risk of Adverse Cardiovascular Events in 5-Year Follow-Up Study of Intermediate...Med Sci Monit In Press; DOI: 10.12659/MSM.943956
Most Viewed Current Articles
17 Jan 2024 : Review article
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952